Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression

BACKGROUND: Less than 30% of malignant gliomas respond to adjuvant chemotherapy. Here, we have asked whether variations in the constitutive expression of early-growth response factor 1 (EGR-1) predicted acute cytotoxicity and clonogenic cell death in vitro, induced by six different chemotherapics. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Calogero, Antonella, Porcellini, Antonio, Lombari, Vincenza, Fabbiano, Cinzia, Arcella, Antonietta, Miscusi, Massimo, Ponti, Donatella, Ragona, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059282/
https://www.ncbi.nlm.nih.gov/pubmed/21366897
http://dx.doi.org/10.1186/1475-2867-11-5
Descripción
Sumario:BACKGROUND: Less than 30% of malignant gliomas respond to adjuvant chemotherapy. Here, we have asked whether variations in the constitutive expression of early-growth response factor 1 (EGR-1) predicted acute cytotoxicity and clonogenic cell death in vitro, induced by six different chemotherapics. MATERIALS AND METHODS: Cytotoxicity assays were performed on cells derived from fresh tumor explants of 18 human cases of malignant glioma. In addition to EGR-1, tumor cultures were investigated for genetic alterations and the expression of cancer regulating factors, related to the p53 pathway. RESULTS: We found that sensitivity to cisplatin correlates significantly with levels of EGR-1 expression in tumors with wild-type p53/INK4a/p16 status. CONCLUSION: Increased knowledge of the mechanisms regulating EGR-1 expression in wild-type p53/INK4a/p16 cases of glioma may help in the design of new chemotherapeutic strategies for these tumors.

Ejemplares similares